Retrospective database analysis of 374,229 patients in the USA, showing higher cases, lower hospitalizations, and no change in mortality with famotidine use.
risk of death, no change, HR 1.00, p = 1.00, vs. never used.
|
risk of hospitalization, 6.0% lower, HR 0.94, p < 0.001, vs. never used.
|
risk of case, 12.0% higher, HR 1.12, p < 0.001, vs. never used.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
This study is excluded in the after exclusion results of meta
analysis:
not fully adjusting for the different baseline risk of systemic autoimmune patients.
Fung et al., 10/1/2021, retrospective, population-based cohort, USA, North America, peer-reviewed, 6 authors.